PubMed Health⌕ Search

Biomedical subjects

Joel Handler

Publications and source records attributed to Joel Handler.

At least 19 recordsLinked to original sources
PubMed2006

Resistant or difficult-to-treat hypertension.

Following a hypertension symposium in Los Angeles, CA, in October 2005, an expert panel discussion was held to discuss resistant hypertension. Are there patients whose blood pressures cannot be controlled? Do inappropriate uses of medications or drug combinations or, on the other hand, poor adherence on the part of patients, play a major role in resistance? Dr. Marvin Moser, Clinical Professor of Medicine at the Yale University School of Medicine, New Haven, CT, moderated the discussion. Participants on this panel included Dr. William Cushman of the University of Tennessee College of Medicine, Memphis, TN, and Dr. Joel Handler of the Kaiser Permanente Group in Anaheim, CA.

Antihypertensive Agents↗
PubMed2005

Secondary hypertension--whom and how do you study? What type of therapy is appropriate?

Following a hypertension symposium in Los Angeles, CA on October 20, 2004, a roundtable was convened to discuss secondary or treatable forms of high blood pressure, when and whom should be studied, and treatment methods. Dr. Marvin Moser, Clinical Professor of Medicine at Yale University School of Medicine, New Haven, CT, moderated the panel discussion. Participants included Dr. Ron Victor, from the Southwestern Medical Center, Dallas, TX and Dr. Joel Handler of the Orange County Kaiser Permanente Hypertension Clinic, Anaheim, CA.

Antihypertensive Agents↗
PubMed2005

Quality of life and antihypertensive drug therapy.

Quality of life on antihypertensive therapy is an important consideration because clinicians are asked to initiate drug therapy and follow mostly asymptomatic patients for long periods of time on agents that are fairly equivalent in both blood-pressure-lowering capacity and the reduction of adverse clinical events. There is, however, evidence to show that hypertension is not always an asymptomatic condition; therefore, the reduction of blood pressure makes people not previously knowledgeable of their hypertensive state feel better. Labeling a patient hypertensive may have negative quality-of-life consequences. Clinicians need to be well informed regarding side-effect profiles as well as anxiety conditions that may lead to subjective complaints that are blamed on medication. Additionally, medication information given to patients may have an important effect on adverse effect reporting. Specific intolerance profiles to the thiazides, angiotensin-converting enzyme inhibitors, beta blockers, calcium channel blockers, and angiotensin receptor blockers are discussed in this review. Medication compliance requires a multi-tiered strategy. Low-dose thiazide is well tolerated.

Adrenergic beta-Antagonists↗
PubMed2005

Changes in the continuation of antihypertensive drug use after ALLHAT.

An analysis was performed of the 1-year continued use of various antihypertensive agents in a health maintenance organization following the 2002 publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Computer-stored information was used from the health maintenance organization's prescription information system. Only patients newly started on antihypertensive medications in 2001 and the calendar year following the ALLHAT publication were analyzed. Patients were considered to be persistent with their first prescribed antihypertensive drug class if they obtained at least one refill for the same class of antihypertensive agents on or within 3 months of the end of the 1-year follow-up period. The overall 1-year continuation rate decreased from 2001 to 2003. However, the continuation of thiazide-type diuretic use after ALLHAT (2003) was higher than that before ALLHAT (2001) (p=0.004), whereas the continuation rate was lower for all other drug classes. We provide data to suggest that evidence from randomized trials is one factor influencing the continued use of antihypertensive medication.

Aged↗